Webull recently experienced a remarkable surge in its share price, climbing 127% over the last quarter. A likely contributor to this impressive performance was the company's addition to the NASDAQ Composite Index on April 14, 2025, which significantly boosted its market profile. While the broader market remained steady over the past week and reported a 6% increase over the last year, Webull's inclusion in the index likely added significant weight to its exceptional rally, drawing increased attention from investors amidst predictions of a 13% annual earnings growth across the market.
We've identified 3 risks with Webull (at least 2 which are a bit unpleasant) and understanding the impact should be part of your investment process.
Rare earth metals are the new gold rush. Find out which 24 stocks are leading the charge.
Over the last year, Webull Corporation's total shareholder returns, including share price and dividends, reached 137.53%. This impressive performance significantly outpaced the broader US market, which returned 4.6% during the same period. Additionally, Webull outperformed the US Capital Markets industry, which achieved a 13.7% return.
The surge in Webull's share price, highlighted by its recent inclusion in the NASDAQ Composite Index, likely contributed to increased investor confidence. However, despite these gains, the company's current share price is notably higher than the estimated fair value of US$3.53, suggesting possible overvaluation concerns. The entry into the Thai market with new services could potentially impact future revenue and earnings forecasts, although current earnings remain unprofitable, with earnings at US$1.15 billion. This volatility and rapid growth escalation should be closely monitored against the backdrop of substantial dilution and high Price-To-Sales Ratio compared to industry peers. Investors might need to consider how these factors align with their investment strategies amidst the company's elevated valuation.
Dive into the specifics of Webull here with our thorough balance sheet health report.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NasdaqCM:BULL.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.